On January 12, 2026, Mirum Pharmaceuticals, Inc. announced its preliminary unaudited net product sales for the fiscal year 2025, which includes sales of LIVMARLI, CHOLBAM, and CTEXLI, along with a posting of a corporate presentation related to the J.P. Morgan Healthcare Conference.